I AM BUILDING BETTER FRIENDSHIPS

I AM MORE THAN MY ADHD



Xenidate XL®

(Methylphenidate hydrochloride)

Provided as a service to patient education by Viatris. For patients prescribed Xenidate®. Always refer to the patient information leaflet for detailed instructions.

Copyright © 2022 Viatris All rights reserved.

Job number: MET-2022-0004 Date of preparation: March 2022





(Methylphenidate hydrochloride)

Why has my child been switched to Xenidate XL®?

Xenidate XL® contains the same active ingredient (methylphenidate hydrochloride) as Concerta XL® but has a different brand name.

Switching people's medication to generic medicines is one of the common ways the NHS helps ensure their resources are available to everyone who needs them. Your child will only have their medicine switched if their doctor is sure the change won't affect your child's care.

Brand name	Xenidate XL®	Concerta XL®
Generic name	Methylphenidate	Methylphenidate
	hydrochloride	hydrochloride

What is Xenidate XL®?

Xenidate XL® is a medicine that helps improve the activity of certain parts of the brain which are underactive in children with ADHD. Xenidate XL® can help your child at school and at home by improving their attention and concentration, and helping to reduce their impulsive behaviour.

Xenidate XL® contains the same active ingredient as Concerta XL® (methylphenidate hydrochloride).





How does Xenidate XL® compare to Concerta XL®?

Xenidate XL® is a tested and approved medicine for children with attention deficit hyperactivity disorder (ADHD).

Compared to Concerta XL®, Xenidate XL®:

Contains the same active ingredient Methylphenidate hydrochloride.

■ Same method of administration

Once each day in the morning with a glass of water. Xenidate XL® 27mg, 36mg and 54mg tablets can be divided into equal doses, however must not be crushed or chewed.

■ Treats the same condition

For children with ADHD. Your child should always take this medicine exactly as their doctor or pharmacist has told you.

Check with their doctor or pharmacist if you are not sure.

Your child should take Xenidate XL® once each day in the morning with a glass of water.



Does Xenidate XL® cause side effects?

Like all medicines, Xenidate XL® may cause side effects. Some children may experience slow growth when taking medicines containing methylphenidate so your doctor will monitor your child closely. The treatment can be stopped for a short time to help, and you could also print off a measurement tracker from the Xenidate XL® patient website to help you monitor your child at home.





For more information about Xenidate XL®, visit: www.xenidate.co.uk/en-gb/patient

- Information about switching medicines
- All about Xenidate XL®
- Relaxation exercises to help ADHD
- Day-to-day support materials

You can also find more information in the leafet inside the medicine package.

Reporting of side effects:

If you get any side effects or have a device failure, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report side effects or device failures with any medicine or vaccine to the medicines regulator MHRA through the Yellow Card Scheme. It is easiest and quickest to report side effects and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary), by emailing yellowcard@mhra.gov.uk, by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789, or by downloading and printing a form from the Yellow Card section of the MHRA website. You can also report side effects and device failures direct to the marketing authorisation holder at pv.uk@viatris.com.





(Methylphenidate hydrochloride)

Provided as a service to patient education by Viatris. For patients prescribed Xenidate®. Always refer to the patient information leaflet for detailed instructions.

Copyright © 2022 Viatris All rights reserved. Job number: MET-2022-0004 Date of preparation: March 2022

